Ambev SA ADR (ABEV)vsIDEXX Laboratories Inc (IDXX)
ABEV
Ambev SA ADR
$3.29
+0.30%
CONSUMER DEFENSIVE · Cap: $53.50B
IDXX
IDEXX Laboratories Inc
$560.11
-2.11%
HEALTHCARE · Cap: $45.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Ambev SA ADR generates 1884% more annual revenue ($88.21B vs $4.45B). IDXX leads profitability with a 24.6% profit margin vs 17.7%. ABEV appears more attractively valued with a PEG of 2.31. IDXX earns a higher WallStSmart Score of 63/100 (C+).
ABEV
Buy57
out of 100
Grade: C
IDXX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+74.4%
Fair Value
$11.91
Current Price
$3.29
$8.62 discount
Margin of Safety
-41.2%
Fair Value
$459.52
Current Price
$560.11
$100.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Generating 11.6B in free cash flow
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 26.5%
Every $100 of equity generates 73 in profit
Strong operational efficiency at 31.8%
Keeps 25 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
2.2% earnings growth
Revenue declined 0.1%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 27.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABEV
The strongest argument for ABEV centers on Free Cash Flow, Market Cap, P/E Ratio. Profitability is solid with margins at 17.7% and operating margin at 26.5%.
Bull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Profit Margin. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bear Case : ABEV
The primary concerns for ABEV are PEG Ratio, EPS Growth, Revenue Growth.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 42.0x leaves little room for execution misses.
Key Dynamics to Monitor
ABEV profiles as a declining stock while IDXX is a mature play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.57 — expect wider price swings.
IDXX is growing revenue faster at 14.3% — sustainability is the question.
ABEV generates stronger free cash flow (11.6B), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (63/100 vs 57/100), backed by strong 24.6% margins and 14.3% revenue growth. ABEV offers better value entry with a 74.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ambev SA ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Ambev SA produces, distributes and sells beer, draft beer, carbonated soft drinks (CSD), other non-alcoholic beverages, malt and food products in the Americas. The company is headquartered in So Paulo, Brazil.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Compare with Other BEVERAGES - BREWERS Stocks
Want to dig deeper into these stocks?